Melanoma and Body Image

Facing melanoma or any cancer isn’t just a physical journey — it impacts your mind, emotions, relationships, and sense of self. In this episode, Dr. Rena Szabo, PsyD, a clinical psychologist specializing in psycho-oncology, shares insights on how a holistic, person-centered approach can support patients and caregivers throughout their cancer experience.
Dr. Szabo discusses practical strategies for building resilience, managing stress and anxiety, and coping with changes to body image, helping patients maintain a sense of control and hope during treatment and survivorship. She also highlights how healthcare providers can better support patients by addressing mental and emotional well-being alongside physical health.
Tune in for guidance, encouragement, and a compassionate look at caring for yourself through the full spectrum of the cancer journey.
Beyond her clinical work, Dr. Szabo’s passion for programs like Special Olympics’ Strong Minds highlights the importance of mental health support for everyone, no matter the challenge. Her approach is about seeing you as a whole person — not just a patient — and helping you find strength and balance in difficult times.
About Dr. Rena Szabo
Dr. Szabo is a clinical psychologist specializing in psycho-oncology and integrated behavioral health at Banner Health. She’s dedicated to improving the lives of cancer patients by addressing the full spectrum of their needs — mind, body, and spirit. Outside of work, she’s a mom, runner, book lover, and active member of her faith community. Her leadership in Special Olympics Arizona’s Strong Minds program reflects her deep commitment to mental health for all.
Tune in to hear Dr. Szabo’s uplifting message and learn how embracing holistic care can empower you in your cancer journey.
Recent Posts

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

Fifth Annual Evening in Memory of Valerie Guild

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes


